This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Safety, Tolerability, and Efficacy of Monotherapy ...
Clinical trial

Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Adults With Nonalcoholic Steatohepatitis (NASH)

Read time: 2 mins
Last updated:1st Aug 2019
Identifier: NCT03987074

The primary objective of this study is to evaluate the safety and tolerability of study drug(s) in adults with nonalcoholic steatohepatitis (NASH).


Study Type: Interventional  (Clinical Trial)
Estimated Enrollment: 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Subjects With Nonalcoholic Steatohepatitis (NASH)
Estimated Study Start Date: August 2019
Estimated Primary Completion Date: June 2020
Estimated Study Completion Date: July 2020

Arms:
- Experimental:
Semaglutide
- Experimental: Semaglutide + Firsocostat
- Experimental: Semaglutide + Cilofexor 30 mg
- Experimental: Semaglutide + Cilofexor 100 mg
- Experimental: Semaglutide + Firsocostat + Cilofexor

Category Value
Date last updated at source 2019-07-17
Study type(s) Interventional
Expected enrolment 100
Study start date 2019-08-01
Estimated primary completion date 2020-06-01

View full details